NEW YORK - Four players projected to be taken in the middle to low rounds of next week’s NFL draft have tested positive for marijuana, a source said.

The four include two from Wisconsin: defensive tackle Anttaj Hawthorne and guard Jonathan Clinkscale; defensive tackle Eric Coleman of Clemson and safety Atcheson Conway of Bowie, according to a source within the league who spoke to The Associated Press on condition of anonymity.

The tests were administered at the NFL scouting combine, as was the one in which Northwestern defensive tackle Luis Castillo tested positive for androstenedione, which is considered a steroid by the NFL. Castillo, whose draft status was rising quickly before the positive test became public, is considered a potential first- or second-round pick.

Special feature Draft report card — how’d your team do? Rookies who’ll shine  |  Rookies who’ll struggle Team picks, analysis, player ratings, more   PFT: Teams that did well at the draft   PFT: Players in position to shine Rosenthal: The winners and losers PFT: McDaniels says Tebow will only play QB   Slideshow: Happy faces of the draftees Opinion: This year not about QBs, RBs, WRs PFT: Weber St. WR is draft’s ‘Mr. Irrelevant’

Hawthorne is considered the best prospect of the other four, although his stock had been slipping. He could go in the fourth round or lower after being projected as a second-round pick early.

The NFL, which does not disclose information on drug tests, had no comment.

A player who tests positive for street drugs such as marijuana goes into the first stage of the NFL’s drug program. That makes him subject to random testing up to 10 times a month for two years and subject to a fine or suspension if he tests positive again.

A player who tests positive for steroids before he comes into the league is subject to “reasonable cause” testing for steroids up to 24 times a year for his entire career. A player already in the league who tests positive for steroids is subject to suspension as a first-time offender.